A COMPARISON OF PERPHENAZINE, PROKETAZINE, NIALAMIDE AND MO-482 IN CHRONIC SCHIZOPHRENICS
Abstract
Of 25 chronic schizophrenics in each group on perphenazine and proketazine, 11 patients on each drug showed improvement. The patients with delusions, hallucinations and hyperactivity had the maximal benefit from these psychoinhibiting drugs. Of 25 chronic schizophrenics in each group, 11 improved with nialamide and 7 with MO-482. Seven patients on perphenazine and 8 on proketazine improved either to a moderate or marked degree. Moderate to marked improvement was seen in 3 and 5 patients on nialamide and MO-482 respectively. Apathetic and autistic patients had the maximal benefit from the psychoactivating drugs. These drugs are relatively safe as no serious untoward clinical or laboratory results were observed.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
